pharmaceutical-investing CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection 15 January
pharmaceutical-investing CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia 12 January
pharmaceutical-investing CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements 23 December 2025
